Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.

ABSTRACT: Blockade of the inflammatory cytokine tumor necrosis factor (TNF) in depressed patients with increased inflammation has been associated with decreased depressive symptoms. Nevertheless, the impact of TNF blockade on sleep in depressed patients has not been examined. Accordingly, sleep parameters were measured using polysomnography in 36 patients with treatment resistant major depression at baseline and 2weeks after 3 infusions (week 8) of either the TNF antagonist infliximab (n=19) or placebo (n=17). Markers of inflammation including c-reactive protein (CRP) and TNF and its soluble receptors were also assessed along with depression measured by the 17-item Hamilton Depression Rating Scale. No differences in sleep parameters were found as a function of infliximab treatment over time. Neverth

SUBMITTER: Weinberger JF 

PROVIDER: S-EPMC4468009 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature